Published in Genome Res on October 01, 2012
PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell (2013) 2.38
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov (2013) 2.29
The promise of whole-exome sequencing in medical genetics. J Hum Genet (2013) 1.95
TCPA: a resource for cancer functional proteomics data. Nat Methods (2013) 1.64
The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. Cancer Cell (2015) 1.61
CRAVAT: cancer-related analysis of variants toolkit. Bioinformatics (2013) 1.43
The emerging roles of ARID1A in tumor suppression. Cancer Biol Ther (2014) 1.21
ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas. Int J Mol Sci (2013) 1.14
Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated in cancer--mechanisms and potential therapeutic insights. Clin Cancer Res (2013) 1.07
PI3K pathway dependencies in endometrioid endometrial cancer cell lines. Clin Cancer Res (2013) 1.04
Systematically differentiating functions for alternatively spliced isoforms through integrating RNA-seq data. PLoS Comput Biol (2013) 1.04
Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition. Oncotarget (2014) 1.03
Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. J Natl Cancer Inst (2014) 1.03
SWI/SNF chromatin remodeling complexes and cancer. Am J Med Genet C Semin Med Genet (2014) 1.03
Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations. Cancer Res (2015) 1.01
Identifying molecular drivers of gastric cancer through next-generation sequencing. Cancer Lett (2012) 1.01
Cancer Systems Biology: a peek into the future of patient care? Nat Rev Clin Oncol (2014) 1.01
Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma. Am J Surg Pathol (2013) 1.00
In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proc Natl Acad Sci U S A (2014) 0.99
Cancer whole-genome sequencing: present and future. Oncogene (2015) 0.95
The emerging genomic landscape of endometrial cancer. Clin Chem (2013) 0.94
Disruption of Ttll5/stamp gene (tubulin tyrosine ligase-like protein 5/SRC-1 and TIF2-associated modulatory protein gene) in male mice causes sperm malformation and infertility. J Biol Chem (2013) 0.93
Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution. Genome Biol (2014) 0.92
The PI3K/AKT Pathway and Renal Cell Carcinoma. J Genet Genomics (2015) 0.90
Designing a high-throughput somatic mutation profiling panel specifically for gynaecological cancers. PLoS One (2014) 0.88
Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma. Clin Lymphoma Myeloma Leuk (2014) 0.88
Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study. Int J Gynecol Pathol (2016) 0.88
A central role for TRPS1 in the control of cell cycle and cancer development. Oncotarget (2014) 0.87
Harnessing the genome for characterization of G-protein coupled receptors in cancer pathogenesis. FEBS J (2013) 0.87
RET fusion as a novel driver of medullary thyroid carcinoma. J Clin Endocrinol Metab (2014) 0.87
The roles of ARID1A in gynecologic cancer. J Gynecol Oncol (2013) 0.87
The mutational landscape of endometrial cancer. Curr Opin Genet Dev (2015) 0.86
Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53. Obstet Gynecol Int (2013) 0.86
G-protein-coupled receptor GPR161 is overexpressed in breast cancer and is a promoter of cell proliferation and invasion. Proc Natl Acad Sci U S A (2014) 0.85
Loss of ARID1A expression is associated with poor prognosis in patients with stage I/II clear cell carcinoma of the ovary. Int J Clin Oncol (2015) 0.85
Genetic Diversity in Normal Cell Populations is the Earliest Stage of Oncogenesis Leading to Intra-Tumor Heterogeneity. Front Oncol (2013) 0.84
Gene expression analysis of early stage endometrial cancers reveals unique transcripts associated with grade and histology but not depth of invasion. Front Oncol (2013) 0.83
Cancer genomics identifies disrupted epigenetic genes. Hum Genet (2013) 0.83
Clinicopathologic and prognostic relevance of ARID1A protein loss in colorectal cancer. World J Gastroenterol (2014) 0.82
The estrogen receptor joins other cancer biomarkers as a predictor of outcome. Obstet Gynecol Int (2013) 0.81
Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. Semin Cancer Biol (2015) 0.79
Chromatin remodeling gene AT-rich interactive domain-containing protein 1A suppresses gastric cancer cell proliferation by targeting PIK3CA and PDK1. Oncotarget (2016) 0.79
Interaction-based discovery of functionally important genes in cancers. Nucleic Acids Res (2013) 0.79
ARID1A gene mutation in ovarian and endometrial cancers (Review). Oncol Rep (2015) 0.78
Development of a robust classifier for quality control of reverse-phase protein arrays. Bioinformatics (2014) 0.78
YAP/TAZ regulates the insulin signaling via IRS1/2 in endometrial cancer. Am J Cancer Res (2016) 0.77
Laminin C1 expression by uterine carcinoma cells is associated with tumor progression. Gynecol Oncol (2015) 0.77
Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer. Semin Oncol (2016) 0.77
Feasibility of RNA and DNA extraction from fresh pipelle and archival endometrial tissues for use in gene expression and SNP arrays. Obstet Gynecol Int (2013) 0.77
PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. Mol Oncol (2015) 0.77
Novel genetic targets in endometrial cancer. Expert Opin Ther Targets (2014) 0.77
Novel kinase fusion transcripts found in endometrial cancer. Sci Rep (2015) 0.76
Trps1 regulates biliary epithelial-mesenchymal transition and has roles during biliary fibrosis in liver grafts: a preliminary study. PLoS One (2015) 0.76
Hepatocyte-Specific Arid1a Deficiency Initiates Mouse Steatohepatitis and Hepatocellular Carcinoma. PLoS One (2015) 0.76
Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1. BMC Cancer (2014) 0.76
Transposon mutagenesis identifies genes that cooperate with mutant Pten in breast cancer progression. Proc Natl Acad Sci U S A (2016) 0.76
Identification of novel candidate drivers connecting different dysfunctional levels for lung adenocarcinoma using protein-protein interactions and a shortest path approach. Sci Rep (2016) 0.76
Analyzing Somatic Genome Rearrangements in Human Cancers by Using Whole-Exome Sequencing. Am J Hum Genet (2016) 0.75
The Role of Endocrine G Protein-Coupled Receptors in Ovarian Cancer Progression. Front Endocrinol (Lausanne) (2017) 0.75
Genomic and epigenomic heterogeneity in molecular subtypes of gastric cancer. World J Gastroenterol (2016) 0.75
Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation. Front Oncol (2015) 0.75
Repurposing the Pap smear: one step closer to gynecologic cancer screening. Sci Transl Med (2013) 0.75
Improved survival associated with somatic PIK3CA mutations in copy-number low endometrioid endometrial adenocarcinoma. Oncol Lett (2015) 0.75
Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification. Int J Mol Sci (2017) 0.75
Deletion of Arid1a in Reproductive Tract Mesenchymal Cells Reduces Fertility in Female Mice. Biol Reprod (2016) 0.75
Understanding Molecular Landscape of Endometrial Cancer through Next Generation Sequencing: What We Have Learned so Far? Front Pharmacol (2016) 0.75
Pancancer modelling predicts the context-specific impact of somatic mutations on transcriptional programs. Nat Commun (2017) 0.75
Two Cases of Endometrial Cancer in Twin Sisters with Myotonic Dystrophy. Case Rep Obstet Gynecol (2016) 0.75
HNF1B polymorphism influences the prognosis of endometrial cancer patients: a cohort study. BMC Cancer (2015) 0.75
Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation. Oncotarget (2017) 0.75
The Chromatin Remodeling Component Arid1a Is a Suppressor of Spontaneous Mammary Tumors in Mice. Genetics (2016) 0.75
Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing. Cancer (2017) 0.75
Distribution of somatic mutations of cancer-related genes according to microsatellite instability status in Korean gastric cancer. Medicine (Baltimore) (2017) 0.75
Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer. Cancer Res (2017) 0.75
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst (2000) 16.92
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature (2011) 13.18
ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 13.07
Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov (2005) 11.46
Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res (2011) 10.99
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78
Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res (2005) 7.66
A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet (2005) 6.70
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet (2011) 5.73
Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet (2011) 5.68
A decade's perspective on DNA sequencing technology. Nature (2011) 5.61
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov (2011) 4.78
PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer (2011) 4.37
Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer (2008) 4.25
High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res (2005) 3.98
Understanding the words of chromatin regulation. Cell (2009) 3.67
Making sense of cancer genomic data. Genes Dev (2011) 3.01
ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res (2011) 2.71
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 2.54
Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM). Cancer Biol Ther (2010) 2.33
An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. Oncogene (2011) 2.23
Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol (2011) 2.03
Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol (2011) 1.99
Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J Pathol (2011) 1.91
The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther (2008) 1.90
Ba/F3 cells and their use in kinase drug discovery. Curr Opin Oncol (2007) 1.88
Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res (2008) 1.87
The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br J Cancer (2009) 1.70
Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther (2010) 1.62
PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res (1998) 1.58
PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences. Cancer Lett (2008) 1.52
PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations. Hum Pathol (2006) 1.47
Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene (2002) 1.46
PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters. Mod Pathol (2007) 1.44
Wnt pathway activation: new relations and locations. Cell (2005) 1.43
Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol (2004) 1.39
Regulation of apoptosis by the Ft1 protein, a new modulator of protein kinase B/Akt. Mol Cell Biol (2004) 1.35
Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. Int J Oncol (2004) 1.31
Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma. Gynecol Oncol (2009) 1.29
Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod Pathol (2009) 1.28
Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. Clin Cancer Res (2008) 1.21
Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia. Am J Clin Pathol (2001) 1.19
Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. Int J Cancer (2011) 1.17
Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 growth factor receptors and their ligands, neuregulin-1 alpha, neuregulin-1 beta, and betacellulin, in normal endometrium and endometrial cancer. Clin Cancer Res (1999) 1.10
Mutational analysis of the CTNNB1 and APC genes in uterine endometrioid carcinoma. Mod Pathol (2000) 1.08
Identification and characterization of RPK118, a novel sphingosine kinase-1-binding protein. J Biol Chem (2002) 1.06
Activins and inhibins in endocrine and other tumors. Endocr Rev (2001) 1.06
Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma. Neoplasia (2009) 1.00
Noncanonical Wnt11 inhibits hepatocellular carcinoma cell proliferation and migration. Mol Cancer Res (2010) 0.98
Activin A inhibits vascular endothelial cell growth and suppresses tumour angiogenesis in gastric cancer. Br J Cancer (2011) 0.98
Expression of the epidermal growth factor system in endometrioid endometrial cancer. Gynecol Oncol (2006) 0.93
High activin A-expression in human neuroblastoma: suppression of malignant potential and correlation with favourable clinical outcome. Oncogene (2005) 0.91
Myeloblastin is a granulocyte colony-stimulating factor-responsive gene conferring factor-independent growth to hematopoietic cells. Proc Natl Acad Sci U S A (2000) 0.91
RPK118, a PX domain-containing protein, interacts with peroxiredoxin-3 through pseudo-kinase domains. Mol Cells (2005) 0.87
Mutational analysis of the CTNNB1 (beta-catenin) gene in human endometrial cancer: frequent mutations at codon 34 that cause nuclear accumulation. Oncol Rep (2000) 0.85
FTS (fused toes homolog) a novel oncoprotein involved in uterine cervical carcinogenesis and a potential diagnostic marker for cervical cancer. J Cell Physiol (2011) 0.83
Regulation of endometrial adenocarcinoma cell proliferation by Activin-A and its modulation by 17beta-estradiol. Mol Cell Endocrinol (2002) 0.82
Expression and function of activin receptors in human endometrial adenocarcinoma cells. Int J Oncol (2003) 0.80
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science (2002) 42.78
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
MicroRNA gene expression deregulation in human breast cancer. Cancer Res (2005) 27.56
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell (2006) 23.59
miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A (2005) 21.51
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
Use of proteomic patterns in serum to identify ovarian cancer. Lancet (2002) 16.38
MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A (2004) 14.59
Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29
A landscape of driver mutations in melanoma. Cell (2012) 12.61
MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA (2008) 12.26
Prepublication data sharing. Nature (2009) 12.24
Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature (2006) 11.86
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature (2012) 11.68
Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov (2005) 11.46
The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 11.21
MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA (2007) 9.97
MicroRNA signatures in human ovarian cancer. Cancer Res (2007) 9.45
The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer (2009) 9.01
The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A (2005) 8.60
Comparative genome sequencing of Drosophila pseudoobscura: chromosomal, gene, and cis-element evolution. Genome Res (2005) 8.38
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
Finishing a whole-genome shotgun: release 3 of the Drosophila melanogaster euchromatic genome sequence. Genome Biol (2002) 8.07
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther (2006) 7.73
E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell (2008) 7.56
Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet (2011) 7.31
A microRNA signature of hypoxia. Mol Cell Biol (2006) 7.24
Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell (2012) 6.80
The genome of the model beetle and pest Tribolium castaneum. Nature (2008) 6.50
Kepler planet-detection mission: introduction and first results. Science (2010) 6.23
The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol (2007) 6.22
Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med (2011) 6.15
Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res (2006) 5.72
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med (2006) 5.70
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
Regulation of inflammatory responses by IL-17F. J Exp Med (2008) 5.56
MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci U S A (2005) 5.54
Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol (2002) 5.52
Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell (2007) 5.40
MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol (2006) 5.40
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res (2007) 5.40
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood (2008) 5.23
Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med (2006) 5.22
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol (2008) 5.19
Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res (2008) 5.16
Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res (2009) 4.92
MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med (2008) 4.91
Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA (2006) 4.87
Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A (2008) 4.79
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov (2011) 4.78
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol (2012) 4.77
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med (2003) 4.69
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med (2004) 4.69
The cells and logic for mammalian sour taste detection. Nature (2006) 4.65
Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem (2007) 4.60
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature (2011) 4.57
Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A (2011) 4.55
Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology (2008) 4.50
Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci U S A (2010) 4.47
A module of negative feedback regulators defines growth factor signaling. Nat Genet (2007) 4.35